Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.47 |
| ▸ | KDM5A | P29375 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21174428 | 0.82 | NPC1 (0.40) | KDM5BKDM5ACYP2D6CYP2C9ADORA3 | |
| SCHEMBL21174140 | 0.78 | CCKBR (0.42) | CYP2D6CYP2C9 | |
| SCHEMBL30751343 | 0.76 | ADORA1 (0.42) | KDM5BKDM5AADORA3ADORA1ADORA2A | |
| SCHEMBL27374320 | 0.76 | ADORA1 (0.42) | KDM5BKDM5AADORA3ADORA1ADORA2A | |
| SCHEMBL21174072 | 0.76 | USP30 (0.43) | CYP2D6CYP2C9ADORA3ADORA1ADORA2B | |
| SCHEMBL21174065 | 0.75 | NPC1 (0.46) | NPC1RAB9A | |
| SCHEMBL21174395 | 0.74 | POLB (0.42) | CYP2D6CYP2C9ADORA1PBKMAPT | |
| SCHEMBL21174174 | 0.73 | NPC1 (0.40) | KDM5BKDM5AADORA3ADORA1ADORA2A | |
| SCHEMBL21174373 | 0.72 | ROCK2 (0.43) | KDM5BCYP2D6CYP2C9NPC1RAB9A | |
| SCHEMBL8235212 | 0.69 | PBK (0.62) | KDM5BKDM5APBK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3514149-B1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-05-18 | — | — | EP | disclosed |
| US-10774083-B2 | Heterocyclic amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-09-15 | — | — | US | disclosed |
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-08 | — | — | US | disclosed |
| EP-3514149-A1 | HETEROCYCLIC AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241566-A1 | HETEROCYCLIC AMIDE COMPOUND | PRSS8, PRSS1, PRSS2 | KDM5B 3523/4885KDM5A 3419/4885CYP2D6 4142/4885 |
| US-10774083-B2 | Heterocyclic amide compound | PRSS8, PRSS1, PRSS2 | KDM5B 3523/4885KDM5A 3419/4885CYP2D6 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.